IP Library Granted Patent US 9,937,117
Granted Patent B2
US 9,937,117 · App. 15/204,506 · Granted Apr 10, 2018

Method of reducing hair loss associated with chemotherapy

Inventor: Philippe Andres (Peymeinade, FR)
Assignee: GALDERMA S.A.
A61K8/4946A61K8/042A61K8/046A61Q7/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,937,117
App. No.
15/204,506
Granted
Apr 10, 2018
Kind
B2
Abstract

A method of reducing hair loss (alopecia) in a patient undergoing or scheduled to undergo chemotherapy is claimed. The method involves administering brimonidine or a pharmaceutically acceptable salt thereof to the site of the hair follicles.

Claims (7)

1. A method of reducing hair loss in a patient scheduled to undergo chemotherapy, the method comprising topically applying a pharmaceutical composition comprising an effective amount of brimonidine or a pharmaceutically acceptable salt thereof to the hair follicles of the patient prior to undergoing the chemotherapy.

2. A method according to claim 1 , wherein the brimonidine or a pharmaceutically acceptable salt thereof is brimonidine tartrate.

3. A method according to claim 1 , wherein the pharmaceutical composition comprises a pharmaceutical carrier selected from the group consisting of a foam, conditioner, hair spray, shampoo, gel, cream, emulsion, and solution.

4. A method according to claim 3 , wherein the pharmaceutical carrier is a foam, conditioner, or hair spray.

5. A method according to claim 1 , wherein the brimonidine or a pharmaceutically acceptable salt thereof is present in an amount of from about 0.05% by weight to about 5% by weight of the composition.

6. A method according to claim 1 , wherein the brimonidine or a pharmaceutically acceptable salt thereof is present in an amount of from about 0.05% by weight to about 2% by weight of the composition.

7. A method according to claim 1 , wherein the pharmaceutical composition is applied three to four hours before the patient is scheduled to undergo chemotherapy.

Assignments (4)
CHANGE OF ADDRESS Recorded Jun 28, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 060541/0374 →
ASSET TRANSFER AGREEMENT Recorded Oct 3, 2021
From: GALDERMA S.A.
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 057698/0295 →
CHANGE OF NAME Recorded Oct 3, 2021
From: NESTLÉ SKIN HEALTH S.A.
To: GALDERMA HOLDING SA
Reel/Frame 057698/0356 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2016
From: ANDRES, PHILIPPE
To: GALDERMA S.A.
Reel/Frame 039273/0058 →
Continuity (2)
Provisional Application 62190342 · Jul 9, 2015
Related Publication 20170007522A1 · Jan 12, 2017